Synonym
Antrafenine HCl, SL 73-033, SL-73-033; SL73-033; SL 73033, SL-73033; SL73033; Stakan, Stakane; Antrafenine hydrochloride
IUPAC/Chemical Name
2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate dihydrochloride
InChi Key
GEZLWXYIFNEJBC-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H26F6N4O2.2ClH/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27;;/h1-11,18-19H,12-17H2,(H,37,38);2*1H
SMILES Code
O=C(OCCN1CCN(C2=CC=CC(C(F)(F)F)=C2)CC1)C3=CC=CC=C3NC4=CC=NC5=CC(C(F)(F)F)=CC=C45.[H]Cl.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
661.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wang Y, Law WK, Hu JS, Lin HQ, Ip TM, Wan DC. Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening. J Chem Inf Model. 2014 Nov 24;54(11):3046-50. doi: 10.1021/ci500503b. Epub 2014 Nov 4. PubMed PMID: 25360897.
2: Normand M, Bergua D, Bouvet JP, Cayotte JL, Gottis M. [Correlation of the cause and composition of renal calculi. Value of morphologic and infrared analysis]. Ann Biol Clin (Paris). 1989;47(1):29-34. Review. French. PubMed PMID: 2648901.
3: Moesch C, Rince M, Raby C, Leroux-Robert C. [Identification of a metabolite of floctafenine in urinary calculi]. Ann Biol Clin (Paris). 1987;45(5):546-50. French. PubMed PMID: 2892454.
4: Daudon M, Moesch C, Marty L, Normand M, Rince M, Leroux-Robert C, Reveillaud RJ. [Antrafenine, urinary calculi and crystalluria]. Therapie. 1986 Nov-Dec;41(6):499-504. French. PubMed PMID: 3810546.
5: Cheymol G, Biour M, Bruneel M, Albengres E, Hamel JD. [Evaluation of a national prospective survey on the undesirable effects of glafenine, antrafenine and floctafenine]. Therapie. 1985 Jan-Feb;40(1):45-50. French. PubMed PMID: 2860731.
6: Caccia S, Conti I, Notarnicola A. In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine. J Pharm Pharmacol. 1985 Jan;37(1):75-7. PubMed PMID: 2858538.
7: Hensby CN, Maloubier A, Civier A, Shroot B, Ortonne JP. A model for studying the anti-prostaglandin activity of drugs in human skin. Br J Dermatol. 1984 Jul;111 Suppl 27:147-51. PubMed PMID: 6743546.
8: Dunn CJ, Prouteau M, Delahaye M, Purcell T, Branceni D. Antrafenine: anti-inflammatory activity with respect to oedema and leucocyte infiltration in the rat. Agents Actions. 1984 Feb;14(2):296-9. PubMed PMID: 6608864.
9: Caccia S, Notarnicola A, Fong MH, Benfenati E. Identification and quantitation of 1-arylpiperazines, metabolites resulting from side-chain cleavage of (4-substituted aryl-1-piperazinyl)alkyl heterocyclic derivatives in rat plasma and brain. J Chromatogr. 1984 Jan 20;283:211-21. PubMed PMID: 6707118.
10: Nicot G, Merle L, Coquelin JP, Valette JP, Lachatre G. [Proteins and urinary enzymes following administration of antrafenine in healthy volunteers]. Therapie. 1983 Jul-Aug;38(4):379-86. French. PubMed PMID: 6648882.
